INDIA GLYCOLS LIMITED

DNV
ISO 9001, ISO 14001, ISO 45001, ISO 50001

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/2026-27/78

17th November, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 500201

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Press Release on Financial Results.

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Press Release being issued by the Company on the captioned subject.

This same is also being hosted on the Company's website at www.indiaglycols.com.

This is for your information and record.

Thanking you,

Yours truly,
For India Glycols Limited

ANKUR JAIN
Digitally signed by ANKUR JAIN
Date: 2026.11.17 14:37:01 +05'30'

Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a

Press Release

Post Scheme of Arrangement, India Glycols reports its first financial results for Q2 FY27
Revenue of Rs. 358.18 Crore and EBITDA of Rs. 39.34 Crore

Noida, November 17th, 2026: India Glycols Limited (NSE: INDIAGLYCO | BSE: 500201) has announced its unaudited standalone financial results for the second quarter (Q2 FY27) and half year (H1 FY27) ended September 30, 2026. These results cover only the Company's continuing operations which retains Biobased Specialty Materials; Sustainable & Performance Chemicals, Gases. Its Spirits & Biofuel Undertaking and its Biopharma Undertaking have been demerged into IGL Spirits Limited and Ennature Bio Pharma Limited, and both are now separately listed. India Glycols' Revenue and EBITDA for the period are as follows:

*Results are not comparable in the context of demerger into three separate entities as detailed in the Note below**

Key Financial Highlights: (Rs. in Crore)

Particulars	**Q2 FY27**	**Q2 FY26**	**Q1 FY27**
Revenue from Operations	358.18	2,410.71	354.64
EBITDA	39.34	160.25	40.21
PAT	11.24	53.94	12.35
Quarterly EPS (in Rs.)	1.68	8.71	1.84

***** *The financial results of India Glycols Limited for Q2 FY27 reflect the continuing operations of the Company following the demerger of its Spirits & Biofuel Undertaking and Biopharma Undertaking into IGL Spirits Limited and Ennature Bio Pharma Limited, respectively*

Key Highlights for Q2 FY27:

On a standalone basis, revenue from operations stood at Rs. 358.18 crore in Q2 FY27, compared to Rs. 2,410.71 crore in the corresponding quarter of the previous year.

EBITDA for Q2 FY27 stood at Rs. 39.34 crore, compared to Rs. 160.25 crore in Q2 FY26.

Profit After Tax (PAT) stood at Rs. 11.24 crore, as against Rs. 53.94 crore in the corresponding quarter of the previous year.

The Q1 FY27 figures have been included in the table for reference. The Q2 FY26 comparative figures are also presented as reported in the previous year and should be read in the context of the demerger.

Performance in H1 FY27

Particulars	H1 FY27	H1 FY26
Revenue from Operations	712.82	4,913.74
EBITDA	79.55	309.51
PAT	23.59	106.79
Half-yearly EPS (in Rs.)	3.52	17.25

***** *The financial results of India Glycols Limited for H1 FY27 reflect the continuing operations of the Company following the demerger of its Spirits & Biofuel Undertaking and Biopharma Undertaking into IGL Spirits Limited and Ennature Bio Pharma Limited, respectively.*

Key Highlights for H1 FY27:

For H1 FY27, India Glycols Limited reported standalone revenue from operations of Rs. 712.82 crore, compared to Rs. 4,913.74 crore in H1 FY26.

EBITDA for H1 FY27 stood at Rs. 79.55 crore, compared to Rs. 309.51 crore in the corresponding period of the previous year.

The Profit After Tax (PAT) for H1 FY27 stood at Rs. 23.59 crore, as against Rs. 106.79 crore in H1 FY26.

Commenting on the results, Mr. Rupark Sarswat, Chief Executive Officer, India Glycols Limited, said, "The implementation of the demerger marks an important step in the evolution of India Glycols, enabling a sharper focus on our core business of bio-based specialities and performance chemicals. We remain focused on strengthening our capabilities, enhancing operational efficiencies and building on our expertise in the bio-based chemicals space. Going forward, our efforts will be directed towards expanding our business opportunities and creating sustainable long-term value for our stakeholders."

Note*: *The Hon'ble National Company Law Tribunal (NCLT), Allahabad Bench, Prayagraj, vide its order dated July 17, 2026, approved the Scheme of Arrangement among India Glycols Limited, IGL Spirits Limited and Ennature Bio Pharma Limited for the demerger of the Spirits and Biofuel Undertaking into IGL Spirits Limited and the Biopharma Undertaking into Ennature Bio Pharma Limited. The Scheme became effective on September 1, 2026, with an appointed date of April 1, 2026. Accordingly, the Spirits and Biofuel Undertaking and the Biopharma Undertaking were demerged and vested in the respective resulting companies as going concerns with effect from the appointed date. The financial results of India Glycols Limited for Q2 FY27 and H1 FY27 do not include the financial performance of these two undertakings. The Q1 FY27 figures have been restated to give effect to the Scheme. The comparative figures for Q2 FY26 and H1 FY26 include the Spirits and Biofuel Undertaking and the Biopharma Undertaking, which have been demerged from the Company with effect from April 1, 2026. Accordingly, these comparative figures are not comparable with the corresponding current-period figures.*